File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Treatment of non-erosive reflux disease with a proton pump inhibitor in Chinese patients: A randomized controlled trial

TitleTreatment of non-erosive reflux disease with a proton pump inhibitor in Chinese patients: A randomized controlled trial
Authors
KeywordsClinical trial
GERD
Proton pump inhibitor
Issue Date2011
PublisherSpringer Japan. The Journal's web site is located at http://link.springer-ny.com/link/service/journals/00535/index.htm
Citation
Journal Of Gastroenterology, 2011, v. 46 n. 7, p. 906-912 How to Cite?
Abstract
Background: Evidence suggests that rates of gastroesophageal reflux disease are increasing in the Asia-Pacific region, where patients tend to have predominantly non-erosive reflux disease as opposed to erosive (reflux) esophagitis. At present, data for the responsiveness of non-erosive reflux disease to proton pump inhibition are scant. We aimed to study esomeprazole for the treatment of non-erosive reflux disease in Chinese patients. Methods: Patients with a clinical diagnosis of gastroesophageal reflux, and a locally validated reflux index, the Chinese GerdQ, of equal to or greater than 12 were recruited and randomized to receive esomeprazole 20 mg daily or placebo for 8 weeks. Reflux index scores, quality of life (SF-36), and the hospital anxiety and depression (HAD) scale and symptom relief were evaluated before, during, and after treatment. Results: A total of 175 patients were randomized. Patients in the esomeprazole group (n = 85) demonstrated statistically significant reductions in their GerdQ index, from 19.45 to 15.37 and to 14.32 (p = 0.013, p = 0.005) at weeks 4 and 8, respectively. Compared to placebo at week 8, 57.1% of patients on esomeprazole found that their symptoms had resolved or were acceptable compared with 37.2% in the placebo group (p = 0.001). There were no statistically significant differences in overall quality-of-life measures or the HAD scale related to treatment. Conclusions: This study suggests that esomeprazole is efficacious in treating Chinese patients with non-erosive reflux disease. © 2011 Springer.
Persistent Identifierhttp://hdl.handle.net/10722/139500
ISSN
2013 Impact Factor: 4.020
2013 SCImago Journal Rankings: 1.724
ISI Accession Number ID
Funding AgencyGrant Number
University of Hong Kong
Funding Information:

We thank AstraZeneca Hong Kong for the supply of the study medicine and the identical placebo tablets. The study was supported by the Simon KY Lee Endowment Professorship, and the outstanding researcher award 2005-2006 of the University of Hong Kong.

References

 

DC FieldValueLanguage
dc.contributor.authorTan, VPYen_HK
dc.contributor.authorWong, WMen_HK
dc.contributor.authorCheung, TKen_HK
dc.contributor.authorLai, KCen_HK
dc.contributor.authorHung, IFNen_HK
dc.contributor.authorChan, Pen_HK
dc.contributor.authorPang, Ren_HK
dc.contributor.authorWong, BCYen_HK
dc.date.accessioned2011-09-23T05:50:42Z-
dc.date.available2011-09-23T05:50:42Z-
dc.date.issued2011en_HK
dc.identifier.citationJournal Of Gastroenterology, 2011, v. 46 n. 7, p. 906-912en_HK
dc.identifier.issn0944-1174en_HK
dc.identifier.urihttp://hdl.handle.net/10722/139500-
dc.description.abstractBackground: Evidence suggests that rates of gastroesophageal reflux disease are increasing in the Asia-Pacific region, where patients tend to have predominantly non-erosive reflux disease as opposed to erosive (reflux) esophagitis. At present, data for the responsiveness of non-erosive reflux disease to proton pump inhibition are scant. We aimed to study esomeprazole for the treatment of non-erosive reflux disease in Chinese patients. Methods: Patients with a clinical diagnosis of gastroesophageal reflux, and a locally validated reflux index, the Chinese GerdQ, of equal to or greater than 12 were recruited and randomized to receive esomeprazole 20 mg daily or placebo for 8 weeks. Reflux index scores, quality of life (SF-36), and the hospital anxiety and depression (HAD) scale and symptom relief were evaluated before, during, and after treatment. Results: A total of 175 patients were randomized. Patients in the esomeprazole group (n = 85) demonstrated statistically significant reductions in their GerdQ index, from 19.45 to 15.37 and to 14.32 (p = 0.013, p = 0.005) at weeks 4 and 8, respectively. Compared to placebo at week 8, 57.1% of patients on esomeprazole found that their symptoms had resolved or were acceptable compared with 37.2% in the placebo group (p = 0.001). There were no statistically significant differences in overall quality-of-life measures or the HAD scale related to treatment. Conclusions: This study suggests that esomeprazole is efficacious in treating Chinese patients with non-erosive reflux disease. © 2011 Springer.en_HK
dc.languageengen_US
dc.publisherSpringer Japan. The Journal's web site is located at http://link.springer-ny.com/link/service/journals/00535/index.htmen_HK
dc.relation.ispartofJournal of Gastroenterologyen_HK
dc.rightsThe original publication is available at www.springerlink.com-
dc.subjectClinical trialen_HK
dc.subjectGERDen_HK
dc.subjectProton pump inhibitoren_HK
dc.subject.meshAnxiety-
dc.subject.meshDouble-Blind Method-
dc.subject.meshGastroesophageal Reflux - drug therapy - psychology-
dc.subject.meshOmeprazole - therapeutic use-
dc.subject.meshProton Pump Inhibitors - therapeutic use-
dc.titleTreatment of non-erosive reflux disease with a proton pump inhibitor in Chinese patients: A randomized controlled trialen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0944-1174&volume=46&issue=7&spage=906&epage=912&date=2011&atitle=Treatment+of+non-erosive+reflux+disease+with+a+proton+pump+inhibitor+in+Chinese+patients:+a+randomized+controlled+trial-
dc.identifier.emailTan, VPY: vpytan@hku.hken_HK
dc.identifier.emailHung, IFN: ivanhung@hkucc.hku.hken_HK
dc.identifier.emailPang, R: robertap@hkucc.hku.hken_HK
dc.identifier.emailWong, BCY: bcywong@hku.hken_HK
dc.identifier.authorityTan, VPY=rp01458en_HK
dc.identifier.authorityHung, IFN=rp00508en_HK
dc.identifier.authorityPang, R=rp00274en_HK
dc.identifier.authorityWong, BCY=rp00429en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s00535-011-0402-1en_HK
dc.identifier.pmid21538030en_HK
dc.identifier.scopuseid_2-s2.0-79960319148en_HK
dc.identifier.hkuros196569en_US
dc.identifier.hkuros203200-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-79960319148&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume46en_HK
dc.identifier.issue7en_HK
dc.identifier.spage906en_HK
dc.identifier.epage912en_HK
dc.identifier.isiWOS:000292607300006-
dc.publisher.placeJapanen_HK
dc.identifier.scopusauthoridTan, VPY=24449627600en_HK
dc.identifier.scopusauthoridWong, WM=7403972413en_HK
dc.identifier.scopusauthoridCheung, TK=7103334158en_HK
dc.identifier.scopusauthoridLai, KC=36177855200en_HK
dc.identifier.scopusauthoridHung, IFN=7006103457en_HK
dc.identifier.scopusauthoridChan, P=7403497841en_HK
dc.identifier.scopusauthoridPang, R=7004376659en_HK
dc.identifier.scopusauthoridWong, BCY=7402023340en_HK
dc.identifier.citeulike9264538-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats